The boom of Sildenafil initially ignited significant growth in the drug sector, generating a image of substantial profits. However, investing in companies primarily reliant on flagship drugs like the erectile dysfunction pill presents substantial challenges. Intellectual property end has resulted in off-brand rivalry, eroding market segment and lik

The recent surge in funding into niche pharmaceutical companies, particularly those focusing on groundbreaking therapies and challenging drug development programs, has fueled what some are calling "High Roller Pharma." While the potential for blockbuster treatments and substantial returns is undeniable, the linked risks are also significant. Many o